Joseph Earley
EOG Resources
4 Papers
Joseph Earley is an academic researcher from EOG Resources. The author has contributed to research in topics: Adeno-associated virus & Genetic enhancement. The author has co-authored 1 publications.
Chat about Author
Papers
Evading and overcoming AAV neutralization in gene therapy.
TL;DR: In this article , the authors discuss the current state and prospects of technologies to evade and overcome these immune responses and allow successful treatment of the greatest number of patients possible, including those with pre-existing immunity and potentially allowing re-administration of a dose in the future, should efficacy wane over time.
31
Epitope Mapping by Molecular Imprinting of Adeno-Associated Virus Serotype 8(AAV8)-Antibody Complexes and Use of Fab Peptides as a Novel Strategy of Evadingneutralisation to Improve the Efficiency of AAV8-Mediated Gene Therapy
Elena V. Piletska,Philippe Veron,Bérangère Bertin,Federico Mingozzi,Donald Jones,Joseph Earley,Kal Karim,Alvaro Garcia Cruz,Sergey A. Piletsky +8 more
Rod-Guide Placement Based on High-Resolution Tortuosity Analysis of Production Tubing
Onyemelem Jegbefume,Jon Bang,Adrián Ledroz,Rob Shoup,Robert Vincent,Joseph Earley +5 more
- 28 Aug 2018
TL;DR: In this paper, the authors developed a method for analyzing the small-scale tortuosity of a wellbore from high-resolution (1ft) survey data, which is used to optimize the rod-pumped system for producing wells.
Analysis of Adeno-Associated Virus Serotype 8 (AAV8)-antibody complexes using epitope mapping by molecular imprinting leads to the identification of Fab peptides that potentially evade AAV8 neutralisation.
Elena V. Piletska,Philippe Veron,Bérangère Bertin,Federico Mingozzi,Donald Jones,Rachel L. Norman,Joseph Earley,Kal Karim,Alvaro Garcia-Cruz,Sergey A. Piletsky +9 more
TL;DR: In this paper , a molecular imprinting technique combined with mass-spectrometry and bioinformatics was used to identify four antigen-binding fragments (Fab) sequences of Adeno-Associated Virus (AAV) -neutralising antibodies capable of binding to AAV.